Nashat Al Sukaiti1, Khwater Ahmed1, Jalila Alshekaili2, Mahmood Al Kindi2, Matthew C Cook3,4,5, Tariq Al Farsi1. 1. Department of Pediatric Allergy and Clinical Immunology, The Royal Hospital, Muscat, Oman. 2. Department of Microbiology and Immunology, Sultan Qaboos University Hospital, Muscat, Oman. 3. Department of Immunology and Infectious Disease, John Curtin School of Medical Research, Australian National University, Canberra, NSW, Australia. 4. Translational Research Unit, Department of Immunology, The Canberra Hospital, Canberra, NSW, Australia. 5. Centre for Personalized Immunology (NHMRC Centre of Research Excellence), John Curtin School of Medical Research, Australian National University, Canberra, NSW, Australia.
Abstract
Introduction: Severe combined immunodeficiency (SCID) results from various monogenic defects that impair immune function and brings on early severe and life-threatening infections. The main stay of treatment for SCID is hematopoietic stem cell transplant (HSCT) with near normal survival at 5 years for an early transplant done at or before the age of 3.5 months of life and the patient is maintained free of infections. Although overall rare, it constitutes a major burden on affected children, their families and on the health system especially in communities with a high rate of consanguinity where incidence and prevalence of recessive inborn errors of immunity (IEI) are expected to be high. Method: Here, we report the clinical, immunological, and molecular findings in 36 children diagnosed with SCID from a single tertiary center in Oman for the last decade. Results: We observed a median annual incidence rate of 4.5 per 100,000 Omani live births, and 91.7% of affected children were born to consanguineous parents. Twenty-three children (63.9%) fulfilled the criteria for typical SCID. The median age at onset, diagnosis and diagnostic delay were 54, 135, and 68 days, respectively. The most common clinical manifestations were pneumonia, septicemia, and chronic diarrhea. Eleven children (30.6%) have received hematopoietic stem cell transplant (HSCT) with a survival rate of 73%. The most frequent genetic cause of SCID in this cohort (n = 36) was (RAG-1), encoding for recombination activating gene (n = 5, 13.9%). Similarly, Major histocompatibility complex type II deficiency accounted for (n = 5, 13.9%) of our cohort. Conclusion: Our report broadens the knowledge of clinical and molecular manifestations in children with SCID in the region and highlights the need to initiate newborn based screening program (NBS) program.
Introduction: Severe combined immunodeficiency (SCID) results from various monogenic defects that impair immune function and brings on early severe and life-threatening infections. The main stay of treatment for SCID is hematopoietic stem cell transplant (HSCT) with near normal survival at 5 years for an early transplant done at or before the age of 3.5 months of life and the patient is maintained free of infections. Although overall rare, it constitutes a major burden on affected children, their families and on the health system especially in communities with a high rate of consanguinity where incidence and prevalence of recessive inborn errors of immunity (IEI) are expected to be high. Method: Here, we report the clinical, immunological, and molecular findings in 36 children diagnosed with SCID from a single tertiary center in Oman for the last decade. Results: We observed a median annual incidence rate of 4.5 per 100,000 Omani live births, and 91.7% of affected children were born to consanguineous parents. Twenty-three children (63.9%) fulfilled the criteria for typical SCID. The median age at onset, diagnosis and diagnostic delay were 54, 135, and 68 days, respectively. The most common clinical manifestations were pneumonia, septicemia, and chronic diarrhea. Eleven children (30.6%) have received hematopoietic stem cell transplant (HSCT) with a survival rate of 73%. The most frequent genetic cause of SCID in this cohort (n = 36) was (RAG-1), encoding for recombination activating gene (n = 5, 13.9%). Similarly, Major histocompatibility complex type II deficiency accounted for (n = 5, 13.9%) of our cohort. Conclusion: Our report broadens the knowledge of clinical and molecular manifestations in children with SCID in the region and highlights the need to initiate newborn based screening program (NBS) program.
Authors: M R Fazlollahi; Z Pourpak; A A Hamidieh; M Movahedi; M Houshmand; M Badalzadeh; M Nourizadeh; M Mahloujirad; S Arshi; M Nabavi; M Gharagozlou; A Khayatzadeh; A Dabbaghzade; L Atarod; F Zandieh; M Sadeghi Shabestary; M Mesdaghi; I Mohammadzadeh; S A Mahdaviani; M H Eslamian; F Pesaran; E Bahraminia; F Abolnezhadian; Z Arij; M Moin Journal: J Investig Allergol Clin Immunol Date: 2017-03-07 Impact factor: 4.333
Authors: Stuart G Tangye; Waleed Al-Herz; Aziz Bousfiha; Talal Chatila; Charlotte Cunningham-Rundles; Amos Etzioni; Jose Luis Franco; Steven M Holland; Christoph Klein; Tomohiro Morio; Hans D Ochs; Eric Oksenhendler; Capucine Picard; Jennifer Puck; Troy R Torgerson; Jean-Laurent Casanova; Kathleen E Sullivan Journal: J Clin Immunol Date: 2020-01-17 Impact factor: 8.317
Authors: Tariq Al Farsi; Khwater Ahmed; Jalila Alshekaili; Mahmood Al Kindi; Matthew Cook; Aliya Al-Hosni; Zainab Ansari; Iman Nasr; Nashat Al Sukaiti Journal: Front Immunol Date: 2022-04-06 Impact factor: 8.786